Cargando…

Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside

Recent advances in basic cardiovascular research as well as their translation into the clinical situation were the focus at the last “New Frontiers in Cardiovascular Research meeting”. Major topics included the characterization of new targets and procedures in cardioprotection, deciphering new playe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabrera-Fuentes, Hector A., Alba-Alba, Corina, Aragones, Julian, Bernhagen, Jürgen, Boisvert, William A., Bøtker, Hans E., Cesarman-Maus, Gabriela, Fleming, Ingrid, Garcia-Dorado, David, Lecour, Sandrine, Liehn, Elisa, Marber, Michael S., Marina, Nephtali, Mayr, Manuel, Perez-Mendez, Oscar, Miura, Tetsuji, Ruiz-Meana, Marisol, Salinas-Estefanon, Eduardo M., Ong, Sang-Bing, Schnittler, Hans J., Sanchez-Vega, Jose T., Sumoza-Toledo, Adriana, Vogel, Carl-Wilhelm, Yarullina, Dina, Yellon, Derek M., Preissner, Klaus T., Hausenloy, Derek J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679108/ https://www.ncbi.nlm.nih.gov/pubmed/26667317 http://dx.doi.org/10.1007/s00395-015-0527-0

Ejemplares similares

From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”
por: Cabrera-Fuentes, Hector A., et al.
Publicado: (2016)

Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning
por: Ferdinandy, Péter, et al.
Publicado: (2023)

ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies
por: Lecour, Sandrine, et al.
Publicado: (2014)

IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
por: Lecour, Sandrine, et al.
Publicado: (2021)

2nd South Africa–United Kingdom cardiovascular workshop
por: Kelly-Laubscher, Roisin, et al.
Publicado: (2012)

Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations
por: Hausenloy, Derek J., et al.
Publicado: (2017)

Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery
por: Hausenloy, Derek J., et al.
Publicado: (2016)

Circadian variation in acute myocardial infarct size assessed by cardiovascular magnetic resonance in reperfused STEMI patients
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

Exosomes and Cardiovascular Protection
por: Davidson, Sean M., et al.
Publicado: (2016)

Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations
por: Hausenloy, Derek J., et al.
Publicado: (2010)

The Role of O-GlcNAcylation for Protection against Ischemia-Reperfusion Injury
por: Jensen, Rebekka Vibjerg, et al.
Publicado: (2019)

Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop
por: Pickard, Jack M. J., et al.
Publicado: (2014)

Reducing myocardial infarct size: challenges and future opportunities
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection—evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology
por: Davidson, Sean M., et al.
Publicado: (2018)

Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting?
por: Kleinbongard, Petra, et al.
Publicado: (2020)

Wake Up and Smell the Coffee: Yet Another No Go for Cardiac Patients?: Editorial to “Caffeinated Coffee Blunts the Myocardial Protective Effects of Statins Against Ischemia–reperfusion Injury in the Rat” by Ye et al.
por: Riksen, Niels P., et al.
Publicado: (2008)

ON NO—The Continuing Story of Nitric Oxide, Diabetes, and Cardiovascular Disease
por: Bøtker, Hans Erik, et al.
Publicado: (2013)

Ischaemic Preconditioning and Postconditioning do not Affect Adenosine A(1) and A(2A) Receptor Sensitivity
por: Riksen, Niels P., et al.
Publicado: (2009)

Preconditioning the diabetic human myocardium
por: Sivaraman, Vivek, et al.
Publicado: (2010)

Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST‐segment elevation myocardial infarction
por: Bøtker, Hans Erik, et al.
Publicado: (2020)

Myocardial Infarct Size Reduction Provided by Local and Remote Ischaemic Preconditioning: References Values from the Hatter Cardiovascular Institute
por: Rossello, Xavier, et al.
Publicado: (2018)

Effect of Remote Ischemic Preconditioning on Acute Kidney Injury in Nondiabetic Patients Undergoing Coronary Artery Bypass Graft Surgery: A Secondary Analysis of 2 Small Randomized Trials
por: Venugopal, Vinod, et al.
Publicado: (2010)

Remote ischaemic conditioning: defining critical criteria for success—report from the 11th Hatter Cardiovascular Workshop
por: Bell, R. M., et al.
Publicado: (2022)

Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning
por: Pickard, Jack M. J., et al.
Publicado: (2016)

Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection
por: Bøtker, Hans Erik, et al.
Publicado: (2018)

An investigation into the effects of simulated ischaemic preconditioning on mitochondrial fusion in mouse embryonic fibroblasts
por: Chew, Ernest J, et al.
Publicado: (2015)

Mitochondrial fusion and fission proteins as novel therapeutic targets for treating cardiovascular disease
por: Ong, Sang-Bing, et al.
Publicado: (2015)

The Diabetic Heart: Too Sweet for Its Own Good?
por: Whittington, Hannah J., et al.
Publicado: (2012)

Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning
por: Hausenloy, Derek J., et al.
Publicado: (2010)

The Akt1 isoform is an essential mediator of ischaemic preconditioning
por: Kunuthur, Suma P, et al.
Publicado: (2012)

Glia, sympathetic activity and cardiovascular disease
por: Marina, Nephtali, et al.
Publicado: (2016)

Exogenous Administration of Recombinant MIF at Physiological Concentrations Failed to Attenuate Infarct Size in a Langendorff Perfused Isolated Mouse Heart Model
por: Rossello, Xavier, et al.
Publicado: (2016)

Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis
por: Bulluck, Heerajnarain, et al.
Publicado: (2018)

Cardiovascular magnetic resonance in cardiac sarcoidosis with MR conditional pacemaker in situ
por: Quarta, Giovanni, et al.
Publicado: (2011)

Cardiovascular Benefits of Dietary Melatonin: A Myth or a Reality?
por: Jiki, Zukiswa, et al.
Publicado: (2018)

Role of the COP9 Signalosome (CSN) in Cardiovascular Diseases
por: Milic, Jelena, et al.
Publicado: (2019)

Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC‐ONC Study—A Single‐Center, Blinded, Randomized Controlled Trial
por: Chung, Robin, et al.
Publicado: (2016)

Rapid assessment of myocardial infarct size in rodents using multi-slice inversion recovery late gadolinium enhancement CMR at 9.4T
por: Price, Anthony N, et al.
Publicado: (2011)

The novel adipocytokine visfatin exerts direct cardioprotective effects
por: Lim, Shiang Y, et al.
Publicado: (2008)

High-sensitivity Troponin-T levels in reperfused STEMI patients: A comparison with CMR
por: Ramlall, Manish, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9uchchbjbgs48rajnk18urallm